Fresenius Kabi signs global licensing deal for Polpharma’s vedolizumab biosimilar
Fresenius Kabi has entered a global licensing agreement for the commercialisation of Polpharma Biologics’s vedolizumab biosimilar candidate PB016, except in…
Gastrointestinal
-
-
Dr Falk Pharma and Allianthera sign agreement for ATB102
Dr Falk Pharma has signed an agreement with Allianthera (Suzhou) Biopharmaceuticals and its affiliate, Allianthera, to co-develop, license, manufacture and…
-
GSK acquires efimosfermin alfa from Boston Pharma for $2bn
GSK has concluded the acquisition of efimosfermin alfa, an investigational therapeutic for serious liver disease (SLD), from Boston Pharmaceuticals in…
-
China’s CDE grants breakthrough status approval to Abbisko’s HCC therapy
The China National Medical Products Administration’s (NMPA) Center for Drug Evaluation (CDE) has granted breakthrough therapy designation approval to Abbisko…
-
J&J’s Tremfya gains EC marketing authorisation for ulcerative colitis
The European Commission (EC) has granted marketing authorisation for Johnson & Johnson's (J&J) Tremfya (guselkumab) to treat adults with moderately…
-
BMS’ Opdivo combo approved in US for hepatocellular carcinoma
The US Food and Drug Administration (FDA) has granted approval for Bristol Myers Squibb’s (BMS) Opdivo (nivolumab) in combination with…
-
FDA approves Johnson & Johnson’s Tremfya to treat Crohn’s disease
Johnson & Johnson (J&J) has received US Food and Drug Administration (FDA) approval for its interleukin 23 inhibitor, Tremfya (guselkumab),…
-
EC approves BMS’ Opdivo and Yervoy combo for HCC
The European Commission (EC) has granted approval for Bristol Myers Squibb’s (BMS) Opdivo (nivolumab) in combination with the recombinant human monoclonal…
-
FDA approves BeiGene’s Tevimbra plus chemo for oesophageal cancer
The US Food and Drug Administration (FDA) has approved BeiGene’s Tevimbra (tislelizumab-jsgr) along with platinum-containing chemotherapy as first-line treatment for…
-
FDA accepts BMS’ Opdivo-Yervoy combo sBLA for colorectal cancer
The US Food and Drug Administration (FDA) has accepted Bristol Myers Squibb’s (BMS) supplemental biologics licence application (sBLA) for an…
